Autoimmune Association Leads Sign-On Letter, Supported by 24 Patient Groups
March 2022- The Autoimmune Association led a sign-on letter supported by 24 organizations calling on Congress to include an increase in its supplemental Covid-19 funding for treatment and prevention through the Biomedical Advanced Research and Development Authority (BARDA) in the FY 2022 omnibus appropriations package.
According to the National Institutes of Health (NIH) and BARDA, several new investigational COVID-19 therapies are completing clinical studies and could be authorized by FDA in the coming weeks and months. We cannot risk delays in the manufacturing and distribution of these new drugs at a time when patients and our health care system need them the most, especially since the COVID-19 pandemic has claimed the lives of nearly 960,000 Americans. Click here to read the full letter.
Join our email list
Receive the latest blog articles, news, and more right to your inbox!
Related articles you might be interested in
Autoimmune Association Leads Sign-On Letter, 64 Patient Groups Ask Congress to Protect Rare Disease Drug Development
Autoimmune Association Leads Sign-On Letter for 2023 NBPP Proposed Rule, Highlights Lack of Language Protecting Copay Assistance
Autoimmune Association and 50+ Patient Groups Send Letter to Key Members of Congress on Drug Pricing Priorities for Autoimmune Patients
Find more resources on autoimmunity
Learn more about autoimmunity, diagnosis tips, how to find a physician, and more.